IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3467
Positioning
Market Dominance
Manufacturing
Measuring And Control Equipment
$384M
Christian O. Henry
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. PacBio's Systems conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 41 | 31 | 50 | 56 | - | - | -1570.3% | -70.6% | 24.9% | -382.2% | -375.8% | 6.7% | 0.0% | 2125.0x | $384M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) receives a "Reduce" rating with a composite score of 40.6/100. It ranks #3467 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for PACB.
View All RatingsROIC -5.2% vs WACC 4.3% (spread -9.5%)
GM 25% vs sector 44%, OM -382% vs sector 3%
Capital turnover 0.07x, R&D intensity 64.5%
Rev growth 7%, 10yr history
Interest coverage -22.4x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) as a Reduce with a composite score of 40.6/100 at a current price of $1.67. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 40.6/100 places it at rank #3467 in our full universe.
No Moat
Very High
Poor
Fair Value
Stable competitive position in a defensive sector.
Leverage of 2125% D/E amplifies downside risk.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. represents a reduce based on multi-factor quantitative performance.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. receives a Reduce rating from our analysis, with a composite score of 40.6/100 and 2 out of 5 stars, ranking #3467 out of 7,333 stocks. PACB's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
PACB's quality score of 31/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -1570.3% (sector avg: -1.9%), gross margins of 24.9% (sector avg: 44.1%), net margins of -375.8% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
PACB's value score of 50/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/B ratio of 13.47x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 6.7% vs. a sector average of 6.7% and a return on assets of -70.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PACB demonstrates moderate momentum with a score of 56/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 6.7% year-over-year, while a beta of 1.66 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
PACB's stability score of 31/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.66 and a debt-to-equity ratio of 2125.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 43/100 for PACB suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 1.66), elevated leverage (D/E: 2125.00x), small-cap liquidity risk. With a $384M market cap (small-cap), PACIFIC BIOSCIENCES OF CALIFORNIA, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3467 of 7,333 overall (53rd percentile). Key comparisons include ROE of -1570.3% trailing the -1.9% sector median and operating margins of -382.2% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PACB currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (31) would have the largest impact on the composite score.
ROE 82548% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 43% BELOW SECTOR MEDIAN
Op. Margin 15327% BELOW SECTOR MEDIAN
Collaboration powers secure international data sharing through the HiFi Solves Global ConsortiumMENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced a collaboration with DNAstack to power the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the collaboration enables secure international research — allowing genomic insights
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 6.3% in the afternoon session after the company announced a collaboration with DNAstack to launch the world's first global federated dataset of HiFi whole genome sequencing data to accelerate rare disease research. This partnership, operating through the HiFi Solves Global Consortium, was designed to enable secure international research. The system allows genomic insights to be shared across borders while the under
Ark Invest has been adding to its positions in Amazon, GitLab, and Pacific Biosciences of California. Amazon's stock hit an all-time high last month, and analysts see further upside. GitLab's recent financial results exceeded expectations, while Pacific Biosciences has struggled but Ark remains a believer in its long-term potential.
The latest update pegs Pacific Biosciences of California’s fair value at US$2.50 per share, compared with the prior US$2.42 anchor, giving investors a fresh reference point for the story. Analysts are using this US$2.50 price target to rethink how they balance valuation, execution and growth potential, with both bullish and bearish voices sharpening their arguments around that figure. As you read on, you will see how this evolving narrative might shape the way you track PacBio from here. Stay...
Above 50MA
37.18%
Net New Highs
+51081